Keytruda takes on 15 advanced cancers in major trial
NCT ID NCT02628067
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests the immunotherapy drug pembrolizumab (Keytruda) in people with 15 types of advanced solid tumors that have worsened after standard treatments. About 1,600 participants receive the drug to see if their tumors shrink or stop growing. The study also looks for biological markers that might predict who benefits most.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab (Keytruda)
- What this could lead to
- If successful, this could show that pembrolizumab helps shrink or control certain advanced cancers that have not responded to other treatments.
- What could go wrong
- This is an early-phase trial with no control group, so results may not confirm real benefit. Not all cancer types may respond, and side effects like immune-related inflammation can occur.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an immunotherapy drug boost the power of chemoradiation against anal cancer?
- Genetic test may spare patients from unnecessary thyroid surgery
- Can your own immune cells beat advanced cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can an antiviral make radiation more effective against cervical cancer?
- What raises endometrial cancer risk in black women? a study digs in